Neurodegenerative Pipeline Progress

Prothena is advancing its early‑to‑mid‑stage pipeline of programs with Bristol Myers, including BMS‑986446 for Alzheimer's Disease and PRX019, a potential treatment for neurodegenerative diseases. The company has completed a phase I study evaluating the safety and pharmacokinetics of single‑dosing administration of PRX019.